About Auron Therapeutics
Auron Therapeutics is a private company based in Wellesley, Massachusetts. It has reported $88,908,475 raised in five offerings on Form D since July 2018. Its chief executive is Katharine Yen.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Aug 10, 2026 | Aug 13, 2026 | $7,118,141of $12.0M target | 14 | $508K | DebtRule 506(b) | Form D ↗ |
| Dec 18, 2024 | Dec 31, 2024amended Dec 23, 2025 | $27,289,180of $42.2M target | 16 | $1.7M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Jul 14, 2022 | Jul 28, 2022amended Oct 20, 2023 | $38,399,997of $48.2M target | 10 | $3.8M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Dec 3, 2020 | Dec 16, 2020 | $15,441,157fully sold | 25 | $617K | EquityRule 506(b) | Form D ↗ |
| Jun 12, 2018 | Jul 25, 2018 | $660,000of $1.5M target | 8 | $82,500 | DebtRule 506(b) | Form D ↗ |
| Total, five offerings | $88,908,475 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Auron Therapeutics's Form D filed Aug 13, 2026.
Briggs Morrison
Director
Also a chief executive officer and director at Crossbow Therapeutics and a director at Reunion Neuroscience.
Alexandra Cantley
Director
Also a director at Cirrus Therapeutics, Crossbow Therapeutics and EpiBiologics.
KY
Katharine Yen
Founder & CEO, director
Earlier filings also listed Eric Shiozaki (director, last listed Oct 2023), Christopher Guiffre (executive officer, last listed Oct 2023), Alon Lazarus (director, last listed Oct 2023), John Higgons (director, last listed Dec 2020) and Isaac Ciechanover (director, last listed Dec 2020).